糖尿病黄斑浮腫治療市場：治療法別、エンドユーザー別-2025-2030年の世界予測

糖尿病黄斑浮腫治療市場は、2023年に29億7,000万米ドルと評価され、2024年には31億2,000万米ドルに達すると予測され、CAGR 5.11％で成長し、2030年には42億2,000万米ドルに達すると予測されています。

糖尿病黄斑浮腫（DME）治療市場には、糖尿病患者の視力障害の主な原因である黄斑部の腫脹を管理することを目的とした治療ソリューションの開発と展開が含まれます。効果的なDME治療の必要性は、関連する眼合併症の発生率を高める糖尿病の世界の有病率の上昇によって強調されています。これらの治療は、視力を維持し、生活の質を向上させ、糖尿病に関連するヘルスケア負担を軽減するために極めて重要です。適用範囲には、抗VEGF注射、コルチコステロイド、レーザー治療などの薬理学的介入が含まれ、主に専門の眼科センターや病院の医療従事者によって使用されます。この領域における主な成長促進要因としては、糖尿病網膜症に対する意識の高まり、治療オプションの進歩、手頃な価格で治療を受けやすくするための支援的な医療政策などが挙げられます。さらに、糖尿病に罹患しやすい世界人口の高齢化が需要を喚起しています。

最近のビジネスチャンスは、持続性ドラッグデリバリーシステムや生物製剤のような患者中心の治療法に現れており、現在進行中の精密医療の研究と一致しています。これらを活用するために、企業は薬剤製剤や包括的治療レジメンの革新に焦点を当てた研究開発やパートナーシップに投資すべきです。しかし、この市場は、先進治療の高額な費用、償還の問題、治療の潜在的な副作用などの課題に直面しており、これが治療の普及を抑制する可能性があります。規制上のハードルも、新規治療法の市場導入を遅らせる要因となっています。今後の技術革新は、非侵襲的治療法と統合ケアアプローチに焦点を当てるべきであり、患者のモニタリングと転帰を強化するためにデジタルヘルス技術を取り入れる可能性もあります。競合情勢を考察すると、市場は断片化されており、主要企業は技術の進歩や戦略的提携を通じて常に差別化を図っています。全体として、DME治療市場の成長は、技術革新とアクセシビリティのバランスにかかっており、持続的な事業成長のためには、技術進歩の受け入れと患者の負担軽減への対応が引き続き重要です。

市場力学：急速に進化する糖尿病黄斑浮腫治療市場の主要市場インサイトを公開

糖尿病黄斑浮腫治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加に伴う世界の糖尿病有病率の上昇
  • 糖尿病網膜症および糖尿病黄斑浮腫に対する認識の高まり
  • 糖尿病性網膜症に対する認識を高めるための政府主導の取り組み
• 市場抑制要因
  • DME治療の高額な治療費
• 市場機会
  • 新しく先進的な治療オプションのイントロダクションの増加
  • DME治療に対する償還政策とヘルスケア適用の改善
• 市場の課題
  • DME治療における臨床試験デザインの課題

ポーターのファイブフォース：糖尿病黄斑浮腫治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：糖尿病黄斑浮腫治療市場における外部からの影響の把握

外部マクロ環境要因は、糖尿病黄斑浮腫治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析糖尿病黄斑浮腫治療市場における競合情勢の把握

糖尿病黄斑浮腫治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス糖尿病黄斑浮腫治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、糖尿病黄斑浮腫治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨糖尿病黄斑浮腫治療市場における成功への道筋を描く

糖尿病黄斑浮腫治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加に伴い糖尿病の世界の罹患率が上昇
    • 糖尿病網膜症と糖尿病黄斑浮腫に対する意識の高まり
    • 糖尿病網膜症に関する意識を高める政府主導の取り組み
  • 抑制要因
    • DME治療の高額な治療費
  • 機会
    • 新しい先進的な治療法のイントロダクションの増加
    • DME治療に対する償還ポリシーとヘルスケア保険の改善
  • 課題
    • DME治療における臨床試験設計の課題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 糖尿病黄斑浮腫治療市場治療別

• コルチコステロイド注射
• 薬物
• レーザー治療
• 薬物治療

第7章 糖尿病黄斑浮腫治療市場：エンドユーザー別

• 病院
• 眼科クリニック

第8章 南北アメリカの糖尿病黄斑浮腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の糖尿病黄斑浮腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの糖尿病黄斑浮腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adverum Biotechnologies
• Aerpio Pharmaceuticals
• Alcon Vision LLC
• Alimera Sciences, Inc.
• Arctic Vision
• Bausch & Lomb Incorporated
• Chugai Pharmaceutical Co., Ltd.
• EyePoint Pharmaceuticals Inc. .
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• GlaxoSmithKline PLC
• Graybug Vision, Inc.
• KalVista Pharmaceuticals, Inc.
• Kodiak Sciences Inc
• Kubota Pharmaceutical Holdings Co. Ltd.
• Novartis AG
• Ocugen Inc.
• Oculis Holding AG
• Ocuphire Pharma, Inc.
• Oxurion NV
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd.
• YD Life Science

LIST OF FIGURES

• FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 23. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 37. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Diabetic Macular Edema Treatment Market was valued at USD 2.97 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 5.11%, to USD 4.22 billion by 2030.

Diabetic Macular Edema (DME) treatment market encompasses the development and deployment of therapeutic solutions aimed at managing swelling in the macula, a primary cause of vision impairment among diabetic patients. The necessity for effective DME treatments is underscored by the rising global prevalence of diabetes, which increases the incidence of associated ocular complications. These treatments are crucial for preserving vision, improving life quality, and reducing healthcare burdens related to diabetes. The application scope includes pharmacological interventions like anti-VEGF injections, corticosteroids, and laser therapy, predominantly used by healthcare providers in specialized ophthalmic centers and hospitals. Key growth drivers in this domain include increased awareness about diabetic retinopathy, advancements in therapeutic options, and supportive health policies facilitating treatment affordability and access. Additionally, the aging global population prone to diabetes catalyzes demand.

Recent opportunities are emerging in patient-centric modalities such as sustained drug delivery systems and biologics, aligning with ongoing research in precision medicine. To leverage these, companies should invest in R&D and partnerships focusing on innovation in drug formulations and comprehensive treatment regimens. However, the market faces challenges like high costs of advanced therapies, reimbursement issues, and potential side effects of treatments that may restrain uptake. Regulatory hurdles can also slow the introduction of novel therapies into the market. Future innovation should focus on non-invasive treatment methods and integrated care approaches, potentially incorporating digital health technologies to enhance patient monitoring and outcomes. Insight into the competitive landscape reveals a fragmented market, with key players constantly striving for differentiation through technology advancement and strategic collaborations. Overall, the growth of the DME treatment market hinges on balancing innovation with accessibility, where embracing technological advancement and addressing patient affordability remain paramount for sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Macular Edema Treatment Market

The Diabetic Macular Edema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising global prevalence of diabetes with increasing geriatric population
  • Increasing awareness of diabetic retinopathy and diabetic macular edema
  • Government-led initiatives to raise awareness about diabetic retinopathy
• Market Restraints
  • High treatment costs of DME treatments
• Market Opportunities
  • Increasing introduction of new and advanced treatment options
  • Improved reimbursement policies and healthcare coverage for DME treatments
• Market Challenges
  • Clinical trial design challenges for DME treatments

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Macular Edema Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Macular Edema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Macular Edema Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Macular Edema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Macular Edema Treatment Market

A detailed market share analysis in the Diabetic Macular Edema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Macular Edema Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Macular Edema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Macular Edema Treatment Market

A strategic analysis of the Diabetic Macular Edema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc. ., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.

Market Segmentation & Coverage

This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Corticosteroid Injections, Drugs, Laser Treatment, and Pharmacological Treatment.
• Based on End-User, market is studied across Hospitals and Ophthalmology Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
    • 5.1.1.2. Increasing awareness of diabetic retinopathy and diabetic macular edema
    • 5.1.1.3. Government-led initiatives to raise awareness about diabetic retinopathy
  • 5.1.2. Restraints
    • 5.1.2.1. High treatment costs of DME treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing introduction of new and advanced treatment options
    • 5.1.3.2. Improved reimbursement policies and healthcare coverage for DME treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Clinical trial design challenges for DME treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Diabetic Macular Edema Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Corticosteroid Injections
• 6.3. Drugs
• 6.4. Laser Treatment
• 6.5. Pharmacological Treatment

7. Diabetic Macular Edema Treatment Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Ophthalmology Clinics

8. Americas Diabetic Macular Edema Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Diabetic Macular Edema Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adverum Biotechnologies
• 3. Aerpio Pharmaceuticals
• 4. Alcon Vision LLC
• 5. Alimera Sciences, Inc.
• 6. Arctic Vision
• 7. Bausch & Lomb Incorporated
• 8. Chugai Pharmaceutical Co., Ltd.
• 9. EyePoint Pharmaceuticals Inc. .
• 10. F. Hoffmann-La Roche Ltd.
• 11. Genentech, Inc.
• 12. GlaxoSmithKline PLC
• 13. Graybug Vision, Inc.
• 14. KalVista Pharmaceuticals, Inc.
• 15. Kodiak Sciences Inc
• 16. Kubota Pharmaceutical Holdings Co. Ltd.
• 17. Novartis AG
• 18. Ocugen Inc.
• 19. Oculis Holding AG
• 20. Ocuphire Pharma, Inc.
• 21. Oxurion NV
• 22. Pfizer Inc.
• 23. Regeneron Pharmaceuticals Inc
• 24. Teva Pharmaceutical Industries Ltd.
• 25. YD Life Science